SAFETY AND ETHICAL CONSIDERATION OF AIDS VACCINE

REFERENCES

• V., Veljkovic, R., Metlas. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene: A warning on AIDS vaccine development. Vaccine. 11: 291–292, 1993, [CSA]
   Google Scholar
• H., Kohler, P. L., Nara, S., Muller. Deceptive imprinting in the immune response to HIV-1 infection. Immunol. Today. 15: 475–478, 1994, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• J., Cohen. The HIV vaccine paradox. Science. 264: 1072–1074, 1994
   PubMed Web of Science ®Google Scholar
• C. P., Locher, R. M., Grant, E. A., Collisson, G., Reyes-Teran, T., Elbeik, J. O., Kahn, J. A., Levy. Antibody and cellular immune responses in breakthrough infection subject after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Human Retrovir.. 71: 1685–1759, 1999
   Google Scholar
• P. W., Berman, A. M., Gray, T., Wrin, J. C., Vennari, D. J., Eastman, G. R., Nakamura, D. P., Francis, G., Gorse, D. H., Schwartz. Genetic and immunologic characterization of virus infecting MN-gp120-vaccinated volunteers. J. Infect. Dis.. 176: 384–397, 1997
   PubMedGoogle Scholar
• R. I., Connor, B. T., Korber, B. S., Graham, B. H, Hahn, D. D., Ho, B. D., Walker, A. U., Neuman, S. H., Vermund, J., Mastecky, S., Jackson, E., Fenmore, Y., Cao, F., Gao, S., Kalmas, K. J., Konstman, D., McDonald, N., McWilliams, A., Trkola, J. P., Moore. Immunological and virological analysis of persons infected by human immunodeficency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol.. 72: 1552–1576, 1998, [CSA]
   PubMed Web of Science ®Google Scholar
• H., Kohler, S., Muller, P. L., Nara. Why AIDS vaccines that induce humoral immunity may not work. The Immunologist. 3: 32–34, 1995, [CSA]
   Google Scholar
• R., Metlas, V., Veljkovic. Does the HIV-1 manipulate immune network via gp120 immunoglobulin like domain involving V3 loop?. Vaccine. 13: 355–359, 1995, [CSA], [CROSSREF]
   Google Scholar
• V., Veljkovic, E., Johnson, R., Metlas. Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Vaccine. 15: 437–438, 1997
   Google Scholar
• D., Gold. IAVI launches project to develop oral HIV vaccine. IAVI Report, April–June, 2000
   Google Scholar
• A., Charbit, P., Martineau, J., Ronco, C., Leclerc, R., Lo-Man, V., Michel, D., O'Callaghan, M.Hofnung. Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine. 11: 1221–1228, 1993, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. M., Hone, G. K., Lewis, M., Beier, A., Harris, T., McDaniels, T. R., Fouts. Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine. Dev. Biol. Stand.. 82: 159–162, 1994, [CSA]
   Google Scholar
• L., Miesel, J. R., Roth. Salmonella recD mutations increase recombination in a short sequence transduction assay. J. Bacteriol.. 176: 4092–4103, 1994
   Google Scholar
• T. R., Fouts, R. G., Tuskan, S., Chada, D. M., Hone, G. K., Lewis. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine. 13: 1697–1705, 1995, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. E., Berggren, A., Wunderlich, E., Ziegler, M., Schleiche, R. C., Duke, D., Looney, F. C., Fang. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol.. 10: 489–495, 1995, [CSA]
   PubMedGoogle Scholar
• D. M., Hone, S., Wu, R. J., Powell, D. W., Pascual, J., Van Cott, J., McGhee, T. R., Fouts, R. G., Tuskan, G. K., Lewis. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic Immune responses. J. Biotechnol.. 44: 203–207, 1996, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E. M., Cattozzo, B. A., Stocker, A., Radaelli, C. De Giuli, Morghen, M., Tognon. Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellin. J. Biotech.. 56: 191–203, 1977, [CROSSREF]
   Google Scholar
• S., Wu, D. W., Pascual, G. K., Lewis, D. M., Hone. Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res. Hum. Retrovir.. 13: 1187–1194, 1997, [CSA]
   PubMed Web of Science ®Google Scholar
• S., Gottlieb. Oral AIDS vaccine to be tested in the Republic of Uganda. Bull. World Health Organ.. 78: 945–946, 2000
   Google Scholar
• G. R., Smith, C. M., Roberts, D. W., Schultz. Activity of Chi recombinational hotspots in Salmonella typhimurium. Genetics. 112: 429–439, 1986, [CSA]
   PubMed Web of Science ®Google Scholar
• L., Miesel, J. R., Roth. Salmonella recD mutations increase recombination in a short sequence transduction assay. J. Bacteriol.. 176: 4092–4103, 1994
   Google Scholar
• G. F., Weiller. Phylogenetic Profiles: A graphical method for detecting genetic recombinations in homologous sequences. Mol. Biol. Evol.. 15: 326–35, 1998, [CSA]
   PubMed Web of Science ®Google Scholar
• C., Rayssiguier, C., Dohet, M., Radman. Interspecific recombination between Escherichia coli and Salmonella typhimurium occurs by the RecABCD pathway. Biochimie. 73: 371–374, 1991, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• I., Matic, M., Radman, C., Rayssiguier. Structure of recombinants from conjugational crosses between Escherichia coli donor and mismatch-repair deficient Salmonella typhimurium recipients. Genetics. 136: 17–26, 1994, [CSA]
   PubMedGoogle Scholar
• I. J., Caley, M. R., Betts, D. M., Irlbeck, N. L., Davis, R., Swanstrom, J. A., Frelinger, R. E., Johnston. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol.. 71: 3031–3038, 1997, [CSA]
   PubMed Web of Science ®Google Scholar
• I. J., Caley, M. R., Betts, N. L., Davis, R., Swanstrom, J. A., Frelinger, R. E., Johnston. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 6: 3124–3135, 1999, [CROSSREF]
   Google Scholar
• E., Eitzen, R., Culpepper, T., Cieslak. Medical Managament of Biological Casualties: Handbook. Frederick, MD, US Army Research, Institute of Infectious Diseases, Fort Detrick. 1999
   Google Scholar
• M. J., Turell, G. V., Ludwig, J., Kondig, J. F., Smith. Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates. Am. J. Trop. Med. Hyg.. 60: 1041–1044, 1999, [CSA]
   Google Scholar
• S. C., Weaver, A., Hagenbaugh, L. A., Bellew, S. V., Netesov, V. E., Volchkov, G. J., Chang, D. K., Clarke, L., Gousset, T. W., Scott, D. W., Trent. A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses. Virology. 197: 375–390, 1993, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T., Rumenapf, E. G., Strauss, J. H., Strauss. Aura virus is a New World representative of Sindbis-like viruses. Virology. 208: 621–633, 1995, [CSA], [CROSSREF]
   Google Scholar
• T. M., Sokolova, L. V., Uryvaev, T. K., Selivanova, O. V., Bobrova, AIu, Lebedev, N. S., Bystrov. Recombination of alpha-viruses during mixed infection in cultured cells. Formation of hybrid forms of RNA of Venezuelan equine encephalomyelitis virus and Karelian fever virus in the region of genes for nucleocapsid and envelope proteins. Vopr. Virusol.. 41: 245–252, 1996, [CSA]
   Google Scholar
• C. G., Murphy, W. T., Lucas, R. E., Means, S., Czajak, C. L., Hale, J. D., Lifson, A., Kaur, R. P., Johnson, D. M., Knipe, R. C., Desrosiers. Vaccine protection agains simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol.. 74: 7745–7754, 2000, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J., Gomez-Marquez, A., Puga, A. L., Notkins. Regions of the terminal repetitions of the herpes simplex virus type 1 genome. J. Biol. Chem.. 260: 3490–3495, 1985
   Google Scholar
• R., Isfort, D., Jones, R., Kost, R., Witter, H. J., Kung. Retroviruses insertion into herpesvirus in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 89: 991–995, 1992, [CSA]
   PubMed Web of Science ®Google Scholar
• R. T., Javier, F., Sedarti, J. G., Stevens. Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science. 234: 746–748, 1986
   PubMed Web of Science ®Google Scholar
• Avret S., Carroll S., Collins C., Green A., Gold D. Nine years and counting: Will we have an HIV vaccine by 2007. AIDS Vaccine Advocacy Coalition Report, May, 1998
   Google Scholar
• O., Picard, J., Lebas, J. C., Imbert, P., Bigel, D., Zagury. Complications of intramuscular/subcutaneous immune therapy in severely immune-compromized individuals. J. Acquir. Immun. Defic. Syndr.. 4: 641–643, 1991, [CSA]
   Google Scholar
• R., Belshe. Phase II safety and immunogenicity trial of live recombinant canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 uninfected adult volunteers. Symposium VI: Progress in HIV Vaccine Development Thirteenth Meeting of the International Society for Sexual Transmitted Diseases Research. 11–14, July 1999, Denver, CO.
   Google Scholar
• L. A., Ball. High-frequency homologous recombination in vaccinia virus DNA. J. Virol.. 61: 1788–1795, 1987, [CSA]
   PubMed Web of Science ®Google Scholar
• D. H., Evans, D., Stuart, G., McFadden. High levels of genetic recombination among cotransfected plasmid DNAs in poxivirus-infected mammalian cells. J. Virol.. 62: 367–375, 1988, [CSA]
   Google Scholar
• B., Moss. Molecular biology of poxviruses, In:. M. M., Binns, G. L., Smith. Recombinant poxiviruses. Boca Raton, FL, CRC Press. 1992; pp. 45–80
   Google Scholar
• K. R., Dumbell, H. S., Bedson. The use of ceiling temperature and reactivation in the isolation of pox virus hybrids. Hygiene (Cambridge). 62: 133–140, 1964, [CSA]
   Google Scholar
• H. S., Bedson, K. R., Dumbell. Hybrids derived from the viruses of alastrim and rabbit pox. J. Hygiene (Cambridge). 62: 141–146, 1964, [CSA]
   Google Scholar
• D., Baxby, R. M., Gaskell, C. J., Gaskell, M., Bennett. Ecology of orthopoxviruses and use of recombinant vaccinia vaccines. Lancet. 11: 850–851, 1986
   Google Scholar
• I., Arita, A., Gromyko. Surveillance of ortopox virus infection, and associated research, in the period after smallpox eradication. Bulletin WHO. 60: 367–374, 1982
   PubMed Web of Science ®Google Scholar
• V. I., Chernos, T. P., Antonova, T. G., Senkevich. Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents. J. Gen. Virol.. 66: 621–626, 1985, [CSA]
   Google Scholar
• V. I., Chernos, T. G., Senkevich, N. V., Chelyapov, T. P., Antonova, T. S., Vovk, I. V., Mitina. Biologic properties of genome structure of the recombinants between ectromelia and rabbitpox viruses. Acta Virol.. 31: 193–202, 1987
   Google Scholar
• D. S., Strayer, G., Cabirac, S., Sell, J. L., Leibowitz. Observations on the culture and histopathologic characteristics of a new virus-induced rabbit tumor. J. Natl. Cancer Inst.. 71: 91–104, 1983
   Google Scholar
• D. S., Strayer, S., Sell. Immunohistology of malignant rabbit fibroma virus – A comparative study with rabbit myxoma virus. J. Natl. Cancer Inst.. 71: 105–116, 1983
   Google Scholar
• D. S., Strayer, S., Sell, E., Skaletsky, J. L., Leibowitz. Immunologic dysfunction during viral oncogenesis. I. Nonspecific immunosuppression caused by malignant rabbit fibroma virus. J. Immunol.. 131: 2595–2600, 1983
   Google Scholar
• D. S., Strayer, E., Skaletsky, G. F., Cabirac, P. A., Sharp, L. B., Corbeil, S., Sell, J. L., Leibowitz. Malignant rabbit fibroma virus causes secondary immunosuppression in rabbits. J. Immunol.. 130: 399–404, 1983
   PubMedGoogle Scholar
• I. D., Ladnyi, P., Ziegler, A., Kima. A human infection caused by monkeypox virus in Basankusu territory, Democratic Republic of the Congo. Bull. WHO. 46: 593–597, 1972
   Google Scholar
• J. G., Breman, R., Kalisa, M. V., Steniowski, E., Zanotto, A. I., Gromyko, I., Arita. Human monkeypox. 1970–1979; Bull. WHO. 58: 165, 1980, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Z., Jezek, B., Grab, M. V., Szczeniowski, K. M., Paluku, M., Mutombo. Human monkeypox: secondary attack rates. Bull. WHO. 66: 465–470, 1988
   PubMed Web of Science ®Google Scholar
• C. P., Czerny, A. M., Eis-Hubinger, A., Mayr, K. E., Schneweis, B., Pfeiff. Animal poxviruses transmitted from cat to man: Current event with lethal end. Zentralbl. Veterinarmed. (B). 38: 421–431, 1991
   Google Scholar
• J. G., Breman, J. H., Nakano, E., Coffi, H., Godfrey, J. C., Gautun. Human poxvirus disease after smallpox eradication. Am. J. Trop. Med. Hyg.. 26: 273–281, 1977
   PubMed Web of Science ®Google Scholar
• J. G., Breman, D. A., Henderson. Poxvirus dilemmas—Monkeypox, smallpox, and biologic terrorism. N. Eng. J. Med.. 339–246: 556, 1998
   Google Scholar
• H. S., Mason, D. M. K., Lam, C. J., Arntzen. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA. 89: 11745–11749, 1992, [CSA]
   PubMed Web of Science ®Google Scholar
• T. A., Haq, H., Mason, J. D., Clements, C. J., Arntzen. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 268: 714–716, 1995
   PubMed Web of Science ®Google Scholar
• P. B., McGarvey, J., Hammond, M. M., Dienelt, D. C., Hooper, Z. F., Fu, B., Dietzschold, H., Koprowski, F. H., Michaels. Expression of the rabies virus glycoprotein in transgenic tomatoes. BioTechnology. 13: 1484–1487, 1995, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. S., Mason, J. M., Ball, J. J., Shi, JX., Jiang, M. K., Estes, C. J., Arntzen. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA. 93: 5335–5339, 1996, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H., Hamamoto, Y., Sugiyama, N., Nakagawa, E., Hashida, Y., Matsunaga, S., Takemoto, Y., Watanabe, Y., Okada. A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato. BioTechnology. 11: 930–932, 1993, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J., Fitchen, R. N., Beachy, M. B., Hein. Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine. 13: 1051–1057, 1993, [CSA], [CROSSREF]
   Google Scholar
• L., McLain, C., Porta, G. P., Lomonossoff, Z., Durrani, N. J., Dimmock. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res. Hum. Retrovir.. 11: 327–334, 1995, [CSA]
   PubMed Web of Science ®Google Scholar
• V., Yusibov, A., Modelska, K., Steplwski, M., Agadjanyan, D., Weiner, D. C., Hooper, H., Koprowski. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl. Acad. Sci. USA. 94: 5784–5788, 1997, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. J., Gibbs, G. F., Weiller. Evidence that a plant virus switched host to infect a vertebrate and than recombined with a vertebrate-infected virus. Proc. Natl. Acad. Sci. USA. 96: 8022–8026, 1999, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. A., Lommel, Z., Xiong. Recombination of a functional red clover necrotic mosaic virus by recombination rescue of the cell-to-cell movement gene expressed in a transgenic plant. J. Cell. Biochem.. 15A: 151–158, 1991
   Google Scholar
• A. E., Greene, R. F., Allison. Recombination between viral RNA and transgenic plant transcripts. Science. 263: 1423–1425, 1994
   PubMed Web of Science ®Google Scholar
• W. M., Wintermantel, J. E., Schoelz. Isolation of recombinant viruses between cauliflower mosaic virus and a viral gene in transgenic plants under conditions of moderate selection pressure. Virology. 223: 156–164, 1996, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• J., Rissler, M., Mellon. The Ecological Risks of Engineered Crops. Cambridge, MA, MIT Press. 1996
   Google Scholar
• J., Esparza. Ethical considerations in HIV preventive vaccine research. UNAIDS guidance document. UNAIDS, Geneve 2000
   Google Scholar
• V., Veljkovic, R., Metlas, H., Kohler, H. B., Urnovitz, J., Prljic, N., Veljkovic, E., Johnson, S., Muller. AIDS epidemic at the beginning of the third millenium: Time for a new AIDS vaccine strategy. Vaccine. 19: 1855–1862, 2001, [CSA], [CROSSREF]
   Google Scholar
• T., Traavik. Comments on risk evaluation of the EURIFEL RCPFeLV combined vaccine, Report of Norwegian Institute of Gene Ecology. 2000
   Google Scholar